Feb 28, 2013 by Brandy BetzMerck's HPV Growth ContinuesGardasil's expanded indications equaled strong sales growth.
Feb 28, 2013 by Brandy BetzA Drug That's Ready to Lose Arena prepares for the upcoming launch of Belviq.
Feb 25, 2013 by Brandy BetzElan Not Keen on Royalty Pharma's $6.6 Billion OfferElan calls the timing "highly opportunistic."
Feb 25, 2013 by Brandy BetzWhat's Next for Dynavax?An FDA denial for its lead drug doesn't equal a death sentence.
Feb 20, 2013 by Brandy BetzMerck's Low Cholesterol Can the company recover from Vytorin's efficacy stumble?
Feb 20, 2013 by Brandy BetzSanofi's GLP-1 Accepted for Review by FDA Does the drug stand a chance in this crowded market?
Feb 19, 2013 by Brandy BetzWill Isis Right Pfizer's Wrong? Phase 2/3 trial initiates for rare genetic condition that spelled trouble for Pfizer.
Feb 18, 2013 by Brandy BetzMerck's Weakest Blockbuster? The rheumatoid arthritis drug shares profits with J&J and could decline with a new threat.
Feb 16, 2013 by Brandy BetzDoes the Arthritis Market Have Growing Pains? Can new drugs find a place among the blockbuster old guard?
Feb 14, 2013 by Brandy BetzMerck's Dynamic Duo Can two diabetes drugs help Merck recover from its patent cliff loss?
Feb 14, 2013 by Brandy BetzWhy Regeneron Shares Dropped TodayThe company fell mid-day following its fourth quarter and annual results.
Feb 13, 2013 by Brandy BetzWhy Seattle Genetics DroppedDid new earnings report cause Seattle Genetics shares to drop?
Feb 12, 2013 by Brandy BetzMerck's Crash of a TitanWhat Singulair's patent expiration means for this big pharma player.
Feb 7, 2013 by Brandy BetzTakeover Rumors Surround This Drug StockEndo Health Solutions looks vulnerable after a rough year
Feb 4, 2013 by Brandy BetzA Cholesterol-Treatment Contender Partners Up Alnylam and The Medicines Company join forces.
Feb 4, 2013 by Brandy BetzSanofi's New Diabetes Play Moves ForwardCould this drug bolster bestselling Lantus as it heads for the patent cliff?
Jan 31, 2013 by Brandy BetzWho Will Win This Small Drug Market?Isis' Kynamro got the FDA stamp this week, but Aegerion has the stronger drug.
Jan 29, 2013 by Brandy BetzWhat's in Regeneron's Pipes? A look at the contenders Regeneron's pushing through its pipeline.
Jan 28, 2013 by Brandy BetzStatins Beware?Will one of these PCSK9 inhibitors become the next Lipitor?
